Hypertension
Conditions
Keywords
High Blood Pressure, Hypertension, Renal Transplantation, Kidney Transplantation
Brief summary
The drug lisinopril is approved by the U.S. Food and Drug Administration for the treatment of high blood pressure, heart failure, and acute heart attacks in adult patients. In children over 6 years of age, lisinopril is approved for the treatment of high blood pressure. Lisinopril is in a group of medications called angiotensin-converting enzyme inhibitors (ACE). ACE inhibitors such as lisinopril work by decreasing certain chemicals that tighten the blood vessels so blood flows more smoothly and the heart can pump blood more efficiently. There is some information available about how children with high blood pressure absorb, distribute, metabolize, and eliminate lisinopril (this information about medication processing by the body is called pharmacokinetic data). However, there is no information about how children with high blood pressure who have received a kidney transplant process lisinopril. In addition to decreasing blood pressure, investigators believe that lisinopril may help kidney transplants work longer by reducing the activity of chemicals made by cells in kidney transplants that can lead to inflammation and injury. Such benefits have not been found with another group of blood pressure medications called calcium channel blockers, which are the most commonly used medication group to control high blood pressure in children after a kidney transplant. A clinical trial will be conducted in the future to compare which medication group helps kidney transplants in children last longer. To guide the selection of the best dose to test in future studies, investigators in this study will try to determine the safety profile, dose tolerability, and pharmacokinetics of lisinopril in children and adolescents (2-17 years of age) who have received a kidney transplant and have high blood pressure.
Interventions
DRUGLisinopril
Subjects will be randomized to Low, Medium, or High dose of Lisinopril
Sponsors
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
The Emmes Company, LLC
University of Rochester
OpAns, LLC
Uptal Patel
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
2 Years to 17 Years
Healthy volunteers
No
Inclusion criteria
1. Kidney transplant recipient 2. Age 2-17 years, inclusive, at the time of first study dose 3. Estimated GFR (eGFR) ≥30 ml/min/1.73m2, with stable allograft function as indicated by \<20% change in serum creatinine in the previous 30 days 4. Stable immunosuppressive regimen, as indicated by \<10% change in dosage (in mg/kg) in these medications, within the 14 days prior to enrollment 5. Systolic BP \>90th percentile for age, gender, and height, necessitating initiation or addition of an antihypertensive medication 6. For females of child-bearing potential, a negative serum pregnancy test prior to initial dosing and agreement to practice appropriate contraceptive measures, including abstinence, from the time of the initial pregnancy testing through the remainder of the study (30 days after last administration of investigational agents).
Exclusion criteria
1. History of anaphylaxis attributable to lisinopril or other angiotensin-converting enzyme inhibitor (ACEI) agents (e.g.,enalapril, ramipril, quinapril) 2. History of anaphylaxis attributable to iohexol or an iodine hypersensitivity 3. Use of an angiotensin-converting enzyme inhibitor (ACEI), angiotensin receptor blocker, or renin antagonist within 30 days prior to enrollment 4. Stage 2 hypertension defined as the \>99th percentile for age, height and gender + 5 mm Hg 5. Blood Potassium value \> 6.0 milliequivalent / liter (mEq/L) (as determined at the screening visit) 6. Previous participation in this study 7. Physician concern that the participant may not adhere to the study protocol, based on prior behavior 8. Current plasmapheresis treatment 9. History of angioedema 10. Pregnancy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Pharmacokinetics (PK) - Area Under the Plasma Concentration-time Curve (AUC) | Day 14 (+/- 3 days) of lisinopril therapy at hours 0 (pre-dose) and 1,2,4,5,8,12 and 24 hrs after dose | At the Day 14 (±3 days) visit, blood (1 mL) will be collected at 0 hour (pre-dose) and at 1, 2, 4, 5, 8, 12 and 24 hours post-lisinopril dose for determination of AUC. Geometric mean was calculated from all measurements. |
| PK - Maximum Observed Concentration of Drug in Plasma (Cmax) | Day14 (+/- 3 d) of dose at 0 hour and 1, 2, 4, 5, 8, 12, and 24 hrs after dose | At the Day 14 (±3 days) visit, blood (1 mL) will be collected at 0 hour (pre-dose) and at 1, 2, 4, 5, 8, 12 and 24 hours post-lisinopril dose for determination of Cmax. Geometric mean was calculated from all measurements. |
| PK - Time of the Maximum Observed Concentration in Plasma (Tmax) | Day 14 (+/- 3 d) of dose at 0 hour and 1, 2, 4, 5, 8, 12, and 24 hrs after dose | At the Day 14 (±3 days) visit, blood (1 mL) will be collected at 0 hour (pre-dose) and at 1, 2, 4, 5, 8, 12 and 24 hours post-lisinopril dose for determination of plasma lisinopril concentration. Medium was calculated from all measurements. |
| PK - Oral Clearance (CL/F) | Day 14 (+/- 3 d) of dose at 0 hour and at 1, 2, 4, 5, 8, 12, and 24 hrs after dose | At the Day 14 (±3 days) visit, blood (1 mL) will be collected at 0 hour (pre-dose) and at 1, 2, 4, 5, 8, 12 and 24 hours post-lisinopril dose for determination of CL/F. Geometric mean was calculated from all measurements. |
| PK Renal Clearance (CLrenal) | Day 14 (+/- 3 d) of dose at 0 hour and 1, 2, 4, 5, 8, 12, and 24 hrs after dose. | At the Day 14 (±3 days) visit, blood (1 mL) will be collected at 0 hour (pre-dose) and at 1, 2, 4, 5, 8, 12 and 24 hours post-lisinopril dose for determination of CLrenal. Geometric mean was calculated from all measurements. |
| Number of Adverse Events (AEs) and Serious Adverse Events (SAEs) During/After Study Drug Administration | First dose of study drug to 30 days after final study visit for AEs and until resolution for SAEs | Number of Adverse Events (AEs) related and not related to study drug; number of Serious Adverse Events (SAEs) related and not related to study drug |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in Systolic Blood Pressure (BP) From Baseline in Lisinopril SOC Group | Screening to Day 14 to 40 | Lisinopril SOC participants were not given the ambulatory blood pressure machine to obtain readings at home, as was the Lisinopril-naive participants. Instead BP measurements were obtained during screening visit and compared to the Day 14 to 40 visit measurements. Note: these participants were not required to attend a Day 14 (+/-3 day visit) but did need to attend sometime between Day 14 to Day 40 (inclusive). The mean of these blood pressure measurements was calculated. |
| Change in Diastolic Blood Pressure From Baseline in Lisinopril-naive Participants | Baseline to Day 14 (+/-3 days) | Ambulatory blood pressure readings were measured during the baseline/pre-study dose period using a SpaceLabs (Redmond, WA) device at home to avoid the confounding effects of venipuncture and abnormal sleep pattern. Another blood pressure reading was performed at 1 day before the final dose of lisinopril (day before the last scheduled visit). The mean of these measurements was calculated. |
| Change in Diastolic Blood Pressure From Baseline in Lisinopril SOC Group | Screening to Day 14 to 40 | Lisinopril SOC participants were not given the ambulatory blood pressure machine to obtain readings at home, as was the Lisinopril-naive participants. Instead BP measurements were obtained during screening visit and compared to the Day 14 to 40 visit measurements (note: the participants were not required to attend a Day 14 (+/-3 day visit) but did need to attend sometime between Day 14 to Day 40. The mean from the blood pressure measurements was calculated. |
| Change in Potassium Level From Baseline in Lisinopril-naive Participants | At baseline visit and Day 14 prior to final study dose. | Potassium values will be obtained at Baseline and Day 14 prior to the final dose of study drug. Mean calculated from the two measurements. |
| Worse Post-dose Decrease in Estimated Glomerular Filtration Rate (eGFR) From Baseline in Lisinopril-naive Participants | Baseline to Day 14 (+/- 3 days) | The eGFR at entry will need to be ≥ 30 ml/min/1.73m\^2 to minimize concerns about an acute angiotensin-converting enzyme inhibitors (ACE-I)-mediated reduction in kidney function. eGFR ratio was computed from the worst post-dose value divided by the Baseline value. |
| Largest eGFR Percent Decrease From Baseline in Lisinopril-naive Participants | Baseline to Day 14 (+/- 3 days) | The eGFR at entry will need to be ≥ 30 ml/min/1.73m\^2 to minimize concerns about an acute angiotensin-converting enzyme inhibitor (ACEI) mediated reduction in kidney function. Largest eGFR percent decrease from baseline reported in results section. |
| Change in Urine Protein/Creatinine From Baseline in Lisinopril-naive Participants. | Baseline to worst post-dose before Day 14 (+/- 3 days) | Change in urine protein/creatinine obtained as follows: Mean change (worst post-dose from baseline) presented for urine protein/creatinine ratio. Geometric mean of the ratio (worst post-dose / baseline with Geometric Coefficient of Variation percent (CV%) and greatest decrease presented for eGFR by dose group. Two patients in the high dose group had an evaluable urine protein/creatinine change. |
| Change in Systolic Blood Pressure From Baseline in Lisinopril-naive Participants | Baseline to Day 14 (+/- 3 days) | Ambulatory blood pressure readings were measured during the baseline/pre-study dose period using a SpaceLabs (Redmond, WA) device at home to avoid the confounding effects of venipuncture and abnormal sleep pattern. Another blood pressure reading was performed at 1 day before the final dose of lisinopril (day before the last scheduled visit). The mean from these measurements was calculated. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Low Dose: Lisinopril Participants will receive study medication for 14±3 days at a dose 0.1 mg/kg/day | 12 |
| Medium Dose: Lisinopril Participants will receive study medication for 14±3 days at a dose 0.2 mg/kg/day | 8 |
| High Dose: Lisinopril Participants will initially receive study medication at 0.2 mg/kg/day for 5±2 days. If blood tests exclude drug-related toxicity, then the lisinopril dose will be increased to 0.4 mg/kg/day and participants will continue to complete the 14±3 day Treatment Period. | 2 |
| Total | 22 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 |
|---|---|---|---|---|
| Overall Study | Insufficient PK sampling | 1 | 2 | 1 |
Baseline characteristics
| Characteristic | Total | High Dose: Lisinopril | Medium Dose: Lisinopril | Low Dose: Lisinopril |
|---|---|---|---|---|
| Age, Continuous | 13.8 years STANDARD_DEVIATION 3 | 9.5 years STANDARD_DEVIATION 3.5 | 13.0 years STANDARD_DEVIATION 3 | 14.9 years STANDARD_DEVIATION 2.3 |
| Estimated glomerular filtration rate (eGFR) | 70.2 ml/min per 1.73m^2 STANDARD_DEVIATION 24.4 | 89.3 ml/min per 1.73m^2 STANDARD_DEVIATION 44.4 | 62 ml/min per 1.73m^2 STANDARD_DEVIATION 16.7 | 72.5 ml/min per 1.73m^2 STANDARD_DEVIATION 25.7 |
| Ethnicity Hispanic/Latino | 4 participants | 0 participants | 2 participants | 2 participants |
| Ethnicity Non-hispanic/non-latino | 18 participants | 2 participants | 6 participants | 10 participants |
| Race (NIH/OMB) American Indian or Alaska Native | 1 Participants | 0 Participants | 1 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 7 Participants | 0 Participants | 4 Participants | 3 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 3 Participants | 0 Participants | 1 Participants | 2 Participants |
| Race (NIH/OMB) White | 11 Participants | 2 Participants | 2 Participants | 7 Participants |
| Region of Enrollment United States | 22 participants | 2 participants | 8 participants | 12 participants |
| Sex: Female, Male Female | 7 Participants | 1 Participants | 2 Participants | 4 Participants |
| Sex: Female, Male Male | 15 Participants | 1 Participants | 6 Participants | 8 Participants |
| Time since transplant | 4.5 years STANDARD_DEVIATION 4.1 | 0.9 years STANDARD_DEVIATION 0.4 | 4.9 years STANDARD_DEVIATION 3.4 | 4.8 years STANDARD_DEVIATION 4.7 |
| Weight | 51.3 kg STANDARD_DEVIATION 23.8 | 23.1 kg STANDARD_DEVIATION 3 | 50.2 kg STANDARD_DEVIATION 28.7 | 56.8 kg STANDARD_DEVIATION 19.4 |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — | — / — |
| other Total, other adverse events | 5 / 12 | 4 / 8 | 2 / 2 |
| serious Total, serious adverse events | 0 / 12 | 1 / 8 | 0 / 2 |
Outcome results
Primary
Number of Adverse Events (AEs) and Serious Adverse Events (SAEs) During/After Study Drug Administration
Number of Adverse Events (AEs) related and not related to study drug; number of Serious Adverse Events (SAEs) related and not related to study drug
Time frame: First dose of study drug to 30 days after final study visit for AEs and until resolution for SAEs
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Low Dose: Lisinopril | Number of Adverse Events (AEs) and Serious Adverse Events (SAEs) During/After Study Drug Administration | AE related to study drug | 5 events |
| Low Dose: Lisinopril | Number of Adverse Events (AEs) and Serious Adverse Events (SAEs) During/After Study Drug Administration | SAE | 1 events |
| Low Dose: Lisinopril | Number of Adverse Events (AEs) and Serious Adverse Events (SAEs) During/After Study Drug Administration | AEs not related to study drug | 7 events |
| Low Dose: Lisinopril | Number of Adverse Events (AEs) and Serious Adverse Events (SAEs) During/After Study Drug Administration | SAE not related to study drug | 1 events |
| Low Dose: Lisinopril | Number of Adverse Events (AEs) and Serious Adverse Events (SAEs) During/After Study Drug Administration | AEs | 12 events |
| Medium Dose: Lisinopril | Number of Adverse Events (AEs) and Serious Adverse Events (SAEs) During/After Study Drug Administration | SAE not related to study drug | 0 events |
| Medium Dose: Lisinopril | Number of Adverse Events (AEs) and Serious Adverse Events (SAEs) During/After Study Drug Administration | AEs | 12 events |
| Medium Dose: Lisinopril | Number of Adverse Events (AEs) and Serious Adverse Events (SAEs) During/After Study Drug Administration | AE related to study drug | 0 events |
| Medium Dose: Lisinopril | Number of Adverse Events (AEs) and Serious Adverse Events (SAEs) During/After Study Drug Administration | AEs not related to study drug | 12 events |
| Medium Dose: Lisinopril | Number of Adverse Events (AEs) and Serious Adverse Events (SAEs) During/After Study Drug Administration | SAE | 0 events |
Primary
Pharmacokinetics (PK) - Area Under the Plasma Concentration-time Curve (AUC)
At the Day 14 (±3 days) visit, blood (1 mL) will be collected at 0 hour (pre-dose) and at 1, 2, 4, 5, 8, 12 and 24 hours post-lisinopril dose for determination of AUC. Geometric mean was calculated from all measurements.
Time frame: Day 14 (+/- 3 days) of lisinopril therapy at hours 0 (pre-dose) and 1,2,4,5,8,12 and 24 hrs after dose
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Low Dose: Lisinopril | Pharmacokinetics (PK) - Area Under the Plasma Concentration-time Curve (AUC) | 298 ng*h/mL | Geometric Coefficient of Variation 46.5 |
| Medium Dose: Lisinopril | Pharmacokinetics (PK) - Area Under the Plasma Concentration-time Curve (AUC) | 640 ng*h/mL | Geometric Coefficient of Variation 28.6 |
| High Dose: Lisinopril | Pharmacokinetics (PK) - Area Under the Plasma Concentration-time Curve (AUC) | 702 ng*h/mL | Geometric Coefficient of Variation 66.4 |
Primary
PK - Maximum Observed Concentration of Drug in Plasma (Cmax)
At the Day 14 (±3 days) visit, blood (1 mL) will be collected at 0 hour (pre-dose) and at 1, 2, 4, 5, 8, 12 and 24 hours post-lisinopril dose for determination of Cmax. Geometric mean was calculated from all measurements.
Time frame: Day14 (+/- 3 d) of dose at 0 hour and 1, 2, 4, 5, 8, 12, and 24 hrs after dose
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Low Dose: Lisinopril | PK - Maximum Observed Concentration of Drug in Plasma (Cmax) | 20.9 ng/ml | Geometric Coefficient of Variation 41.2 |
| Medium Dose: Lisinopril | PK - Maximum Observed Concentration of Drug in Plasma (Cmax) | 47.7 ng/ml | Geometric Coefficient of Variation 25.1 |
| High Dose: Lisinopril | PK - Maximum Observed Concentration of Drug in Plasma (Cmax) | 58.0 ng/ml | Geometric Coefficient of Variation 41.2 |
Primary
PK - Oral Clearance (CL/F)
At the Day 14 (±3 days) visit, blood (1 mL) will be collected at 0 hour (pre-dose) and at 1, 2, 4, 5, 8, 12 and 24 hours post-lisinopril dose for determination of CL/F. Geometric mean was calculated from all measurements.
Time frame: Day 14 (+/- 3 d) of dose at 0 hour and at 1, 2, 4, 5, 8, 12, and 24 hrs after dose
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Low Dose: Lisinopril | PK - Oral Clearance (CL/F) | 17.9 L/h/70 kg | Geometric Coefficient of Variation 61.2 |
| Medium Dose: Lisinopril | PK - Oral Clearance (CL/F) | 18.6 L/h/70 kg | Geometric Coefficient of Variation 34.4 |
| High Dose: Lisinopril | PK - Oral Clearance (CL/F) | 32.8 L/h/70 kg | Geometric Coefficient of Variation 54.1 |
Primary
PK Renal Clearance (CLrenal)
At the Day 14 (±3 days) visit, blood (1 mL) will be collected at 0 hour (pre-dose) and at 1, 2, 4, 5, 8, 12 and 24 hours post-lisinopril dose for determination of CLrenal. Geometric mean was calculated from all measurements.
Time frame: Day 14 (+/- 3 d) of dose at 0 hour and 1, 2, 4, 5, 8, 12, and 24 hrs after dose.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Low Dose: Lisinopril | PK Renal Clearance (CLrenal) | 3.4 L/h/70 kg | Geometric Coefficient of Variation 60.4 |
| Medium Dose: Lisinopril | PK Renal Clearance (CLrenal) | 3.4 L/h/70 kg | Geometric Coefficient of Variation 46 |
| High Dose: Lisinopril | PK Renal Clearance (CLrenal) | 6.8 L/h/70 kg | Geometric Coefficient of Variation 94.4 |
Primary
PK - Time of the Maximum Observed Concentration in Plasma (Tmax)
At the Day 14 (±3 days) visit, blood (1 mL) will be collected at 0 hour (pre-dose) and at 1, 2, 4, 5, 8, 12 and 24 hours post-lisinopril dose for determination of plasma lisinopril concentration. Medium was calculated from all measurements.
Time frame: Day 14 (+/- 3 d) of dose at 0 hour and 1, 2, 4, 5, 8, 12, and 24 hrs after dose
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Low Dose: Lisinopril | PK - Time of the Maximum Observed Concentration in Plasma (Tmax) | 5.0 hours |
| Medium Dose: Lisinopril | PK - Time of the Maximum Observed Concentration in Plasma (Tmax) | 5.0 hours |
| High Dose: Lisinopril | PK - Time of the Maximum Observed Concentration in Plasma (Tmax) | 4.5 hours |
Secondary
Change in Diastolic Blood Pressure From Baseline in Lisinopril-naive Participants
Ambulatory blood pressure readings were measured during the baseline/pre-study dose period using a SpaceLabs (Redmond, WA) device at home to avoid the confounding effects of venipuncture and abnormal sleep pattern. Another blood pressure reading was performed at 1 day before the final dose of lisinopril (day before the last scheduled visit). The mean of these measurements was calculated.
Time frame: Baseline to Day 14 (+/-3 days)
Population: Change in diastolic blood pressure from baseline is reported here for lisinopril-naive participants (not the standard of care group which are reported separately).
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Low Dose: Lisinopril | Change in Diastolic Blood Pressure From Baseline in Lisinopril-naive Participants | eGFR 30-59 ml/min per 1.73m^2 (n=3, 1, 0) | -4.0 mmHg | Standard Deviation 20 |
| Low Dose: Lisinopril | Change in Diastolic Blood Pressure From Baseline in Lisinopril-naive Participants | eGFR >=60 ml/min per 1.73m^2 (n=3, 5, 3) | -9.0 mmHg | Standard Deviation 7.5 |
| Medium Dose: Lisinopril | Change in Diastolic Blood Pressure From Baseline in Lisinopril-naive Participants | eGFR 30-59 ml/min per 1.73m^2 (n=3, 1, 0) | 7.0 mmHg | Standard Deviation 0 |
| Medium Dose: Lisinopril | Change in Diastolic Blood Pressure From Baseline in Lisinopril-naive Participants | eGFR >=60 ml/min per 1.73m^2 (n=3, 5, 3) | -6.0 mmHg | Standard Deviation 6.7 |
| High Dose: Lisinopril | Change in Diastolic Blood Pressure From Baseline in Lisinopril-naive Participants | eGFR 30-59 ml/min per 1.73m^2 (n=3, 1, 0) | NA mmHg | — |
| High Dose: Lisinopril | Change in Diastolic Blood Pressure From Baseline in Lisinopril-naive Participants | eGFR >=60 ml/min per 1.73m^2 (n=3, 5, 3) | -4.0 mmHg | Standard Deviation 5.3 |
Secondary
Change in Diastolic Blood Pressure From Baseline in Lisinopril SOC Group
Lisinopril SOC participants were not given the ambulatory blood pressure machine to obtain readings at home, as was the Lisinopril-naive participants. Instead BP measurements were obtained during screening visit and compared to the Day 14 to 40 visit measurements (note: the participants were not required to attend a Day 14 (+/-3 day visit) but did need to attend sometime between Day 14 to Day 40. The mean from the blood pressure measurements was calculated.
Time frame: Screening to Day 14 to 40
Population: Change in diastolic blood pressure from baseline is reported here for lisinopril SOCparticipants (not the Lisinopril-naive group which are reported separately).
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Low Dose: Lisinopril | Change in Diastolic Blood Pressure From Baseline in Lisinopril SOC Group | eGFR 30-59 ml/min per 1.73m2 (n=2, 2, 0) | -6.0 mmHg | Standard Deviation 5.7 |
| Low Dose: Lisinopril | Change in Diastolic Blood Pressure From Baseline in Lisinopril SOC Group | eGFR >=60 ml/min per 1.73m2 (n=5, 2, 0) | 3.4 mmHg | Standard Deviation 14 |
| Medium Dose: Lisinopril | Change in Diastolic Blood Pressure From Baseline in Lisinopril SOC Group | eGFR 30-59 ml/min per 1.73m2 (n=2, 2, 0) | -6.5 mmHg | Standard Deviation 9.2 |
| Medium Dose: Lisinopril | Change in Diastolic Blood Pressure From Baseline in Lisinopril SOC Group | eGFR >=60 ml/min per 1.73m2 (n=5, 2, 0) | -3.0 mmHg | Standard Deviation 0 |
Secondary
Change in Potassium Level From Baseline in Lisinopril-naive Participants
Potassium values will be obtained at Baseline and Day 14 prior to the final dose of study drug. Mean calculated from the two measurements.
Time frame: At baseline visit and Day 14 prior to final study dose.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Low Dose: Lisinopril | Change in Potassium Level From Baseline in Lisinopril-naive Participants | 0.1 mEq/L | Standard Deviation 0.3 |
| Medium Dose: Lisinopril | Change in Potassium Level From Baseline in Lisinopril-naive Participants | -0.3 mEq/L | Standard Deviation 0.6 |
| High Dose: Lisinopril | Change in Potassium Level From Baseline in Lisinopril-naive Participants | 0.3 mEq/L | Standard Deviation 0.5 |
Secondary
Change in Systolic Blood Pressure (BP) From Baseline in Lisinopril SOC Group
Lisinopril SOC participants were not given the ambulatory blood pressure machine to obtain readings at home, as was the Lisinopril-naive participants. Instead BP measurements were obtained during screening visit and compared to the Day 14 to 40 visit measurements. Note: these participants were not required to attend a Day 14 (+/-3 day visit) but did need to attend sometime between Day 14 to Day 40 (inclusive). The mean of these blood pressure measurements was calculated.
Time frame: Screening to Day 14 to 40
Population: Change in systolic blood pressure from baseline is reported here for lisinopril SOCparticipants (not the Lisinopril-naive group which are reported separately).
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Low Dose: Lisinopril | Change in Systolic Blood Pressure (BP) From Baseline in Lisinopril SOC Group | eGFR 30-59 ml/min per 1.73m2 (n=2, 2, 0) | -6.0 mmHg | Standard Deviation 17 |
| Low Dose: Lisinopril | Change in Systolic Blood Pressure (BP) From Baseline in Lisinopril SOC Group | eGFR >=60 ml/min per 1.73m2 (n=5, 2, 0) | 6.4 mmHg | Standard Deviation 6.9 |
| Medium Dose: Lisinopril | Change in Systolic Blood Pressure (BP) From Baseline in Lisinopril SOC Group | eGFR 30-59 ml/min per 1.73m2 (n=2, 2, 0) | -1.0 mmHg | Standard Deviation 4.2 |
| Medium Dose: Lisinopril | Change in Systolic Blood Pressure (BP) From Baseline in Lisinopril SOC Group | eGFR >=60 ml/min per 1.73m2 (n=5, 2, 0) | -1.0 mmHg | Standard Deviation 0 |
Secondary
Change in Systolic Blood Pressure From Baseline in Lisinopril-naive Participants
Ambulatory blood pressure readings were measured during the baseline/pre-study dose period using a SpaceLabs (Redmond, WA) device at home to avoid the confounding effects of venipuncture and abnormal sleep pattern. Another blood pressure reading was performed at 1 day before the final dose of lisinopril (day before the last scheduled visit). The mean from these measurements was calculated.
Time frame: Baseline to Day 14 (+/- 3 days)
Population: Change in systolic blood pressure from baseline is reported here for lisinopril-naive participants (not the standard of care (SOC) group which are reported separately).
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Low Dose: Lisinopril | Change in Systolic Blood Pressure From Baseline in Lisinopril-naive Participants | eGFR 30-59 ml/min per 1.73m2 (n=3, 1, 0) | -5.0 mmHg | Standard Deviation 11.4 |
| Low Dose: Lisinopril | Change in Systolic Blood Pressure From Baseline in Lisinopril-naive Participants | eGFR >+60 ml/min per 1.732 (n=3, 5, 3) | -6.7 mmHg | Standard Deviation 4 |
| Medium Dose: Lisinopril | Change in Systolic Blood Pressure From Baseline in Lisinopril-naive Participants | eGFR 30-59 ml/min per 1.73m2 (n=3, 1, 0) | -6.0 mmHg | Standard Deviation 0 |
| Medium Dose: Lisinopril | Change in Systolic Blood Pressure From Baseline in Lisinopril-naive Participants | eGFR >+60 ml/min per 1.732 (n=3, 5, 3) | -8.8 mmHg | Standard Deviation 11.7 |
| High Dose: Lisinopril | Change in Systolic Blood Pressure From Baseline in Lisinopril-naive Participants | eGFR 30-59 ml/min per 1.73m2 (n=3, 1, 0) | NA mmHg | — |
| High Dose: Lisinopril | Change in Systolic Blood Pressure From Baseline in Lisinopril-naive Participants | eGFR >+60 ml/min per 1.732 (n=3, 5, 3) | -11.3 mmHg | Standard Deviation 2.1 |
Secondary
Change in Urine Protein/Creatinine From Baseline in Lisinopril-naive Participants.
Change in urine protein/creatinine obtained as follows: Mean change (worst post-dose from baseline) presented for urine protein/creatinine ratio. Geometric mean of the ratio (worst post-dose / baseline with Geometric Coefficient of Variation percent (CV%) and greatest decrease presented for eGFR by dose group. Two patients in the high dose group had an evaluable urine protein/creatinine change.
Time frame: Baseline to worst post-dose before Day 14 (+/- 3 days)
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Low Dose: Lisinopril | Change in Urine Protein/Creatinine From Baseline in Lisinopril-naive Participants. | -0.45 mg/mg | Geometric Coefficient of Variation 0.6 |
| Medium Dose: Lisinopril | Change in Urine Protein/Creatinine From Baseline in Lisinopril-naive Participants. | -0.08 mg/mg | Geometric Coefficient of Variation 0.15 |
| High Dose: Lisinopril | Change in Urine Protein/Creatinine From Baseline in Lisinopril-naive Participants. | -0.74 mg/mg | Geometric Coefficient of Variation 1.37 |
Secondary
Largest eGFR Percent Decrease From Baseline in Lisinopril-naive Participants
The eGFR at entry will need to be ≥ 30 ml/min/1.73m\^2 to minimize concerns about an acute angiotensin-converting enzyme inhibitor (ACEI) mediated reduction in kidney function. Largest eGFR percent decrease from baseline reported in results section.
Time frame: Baseline to Day 14 (+/- 3 days)
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Low Dose: Lisinopril | Largest eGFR Percent Decrease From Baseline in Lisinopril-naive Participants | 15 percentage |
| Medium Dose: Lisinopril | Largest eGFR Percent Decrease From Baseline in Lisinopril-naive Participants | 12 percentage |
| High Dose: Lisinopril | Largest eGFR Percent Decrease From Baseline in Lisinopril-naive Participants | 21 percentage |
Secondary
Worse Post-dose Decrease in Estimated Glomerular Filtration Rate (eGFR) From Baseline in Lisinopril-naive Participants
The eGFR at entry will need to be ≥ 30 ml/min/1.73m\^2 to minimize concerns about an acute angiotensin-converting enzyme inhibitors (ACE-I)-mediated reduction in kidney function. eGFR ratio was computed from the worst post-dose value divided by the Baseline value.
Time frame: Baseline to Day 14 (+/- 3 days)
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Low Dose: Lisinopril | Worse Post-dose Decrease in Estimated Glomerular Filtration Rate (eGFR) From Baseline in Lisinopril-naive Participants | 1 ratio | Geometric Coefficient of Variation 14 |
| Medium Dose: Lisinopril | Worse Post-dose Decrease in Estimated Glomerular Filtration Rate (eGFR) From Baseline in Lisinopril-naive Participants | 1.02 ratio | Geometric Coefficient of Variation 10 |
| High Dose: Lisinopril | Worse Post-dose Decrease in Estimated Glomerular Filtration Rate (eGFR) From Baseline in Lisinopril-naive Participants | 0.89 ratio | Geometric Coefficient of Variation 14 |